Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New pill could replace IV for rare leukemia treatment

NCT ID NCT07504458

First seen Apr 05, 2026 · Last updated May 21, 2026 · Updated 4 times

Summary

This study tests a new oral capsule (QTX-2101) combined with another drug (ATRA) in 150 adults newly diagnosed with low-risk acute promyelocytic leukemia (APL). The goal is to see if the oral version works as well as the standard IV treatment to achieve remission. Participants will take the medication for a set period, but ongoing monitoring for relapse is needed.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE PROMYELOCYTIC LEUKEMIA (APL) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Quetzal Site 1

    RECRUITING

    Duarte, California, 91010, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Quetzal Site 2

    RECRUITING

    The Bronx, New York, 10467, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Quetzal Site 3

    RECRUITING

    Charlottesville, Virginia, 22908, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Quetzal Site 4

    RECRUITING

    Buffalo, New York, 14203, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.